Virginia Arechavala‐Gomeza

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

Sebahattin Çirak, Virginia Arechavala‐Gomeza, Michela Guglieri et al. · The Lancet · 2011 · 862 citations · Full text

Medicine, Neurology, Pharmacotherapy +13

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

Maria Kinali, Virginia Arechavala‐Gomeza, Lucy Feng et al. · The Lancet Neurology · 2009 · 639 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

Muscle histology vs MRI in Duchenne muscular dystrophy

Maria Kinali, Virginia Arechavala‐Gomeza, Sebahattin Çirak et al. · Neurology · 2011 · 154 citations · Full text

Medicine, Neurology, Pathology +17

Comparative Analysis of Antisense Oligonucleotide Sequences for Targeted Skipping of Exon 51 During Dystrophin Pre-mRNA Splicing in Human Muscle

Virginia Arechavala‐Gomeza, Ian R. Graham, Linda Popplewell et al. · Human Gene Therapy · 2007 · 151 citations · Full text

Life Sciences, Genetics, Molecular Biology +14

Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials

Karen Anthony, Sebahattin Çirak, Silvia Torelli et al. · Brain · 2011 · 150 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15